INTRODUCTION:To assess progress against cancer, trends in incidence, survival and mortality need to be interpreted simultaneously.METHODS:Data were obtained from the Kuwait Cancer Registry (KCR) for all Kuwaiti children (0-14 years) and adults (15-99 years) diagnosed with one of 18 common cancers during 2000-2013, with follow-up for vital status to 31 December 2015. World-standardised average annual incidence and mortality rates were calculated for 2000-2004, 2005-2009, 2010-2013. Five-year net survival was estimated with the Pohar Perme estimator, corrected for background mortality using life tables of all-cause mortality. Survival estimates were agestandardised using the International Cancer Survival Standard weights.RESULTS:For liver cancer, five-year net survival increased from 11.4% to 13.4% for patients diagnosed between 2000-2004 and 2010-2013, while incidence and mortality rates fell from 5.5 to 3.6 and from 3.9 to 3.0 per 100,000, respectively. Similar patterns were seen for acute lymphoblastic leukaemia (ALL) and lymphoma in children. Survival and mortality remained stable for cancers of the lung, cervix and ovary, but incidence declined from 10.2 to 7.4, 4.9 to 2.4 and 5.8 to 4.3 per 100,000, respectively. For breast cancer, survival increased from 68.3% to 75.2%, while incidence and mortality rose from 45.6 to 58.7 and from 5.8 to 12.8 per 100,000, respectively. For colon cancer, incidence and mortality rates rose from 11.4 to 12.6 and from 2.3 to 5.4 per 100,000, respectively. Five-year survival fell from 64.8% to 50.2% between 2000-2004 and 2005-2009, before rising to 58.5% for 2010-2013.CONCLUSION:Increasing survival, alongside falling incidence and mortality rates, represents progress in cancer control, attributable to effective prevention (e.g. tobacco control and lung cancer) and early diagnostic activity (e.g. mammography for breast cancer), or better treatment (e.g. childhood ALL). The increasing prevalence of obesity, linked to rising incidence for breast and colon cancers, suggests the need for public health prevention campaigns.

Background Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. Methods We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. Results The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. Conclusions To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.

INTRODUCTION Global variations in survival for brain tumours are very wide when all histological types are considered together. Appraisal of international differences should be informed by the distribution of histology, but little is known beyond Europe and North America. PATIENTS AND METHODS The source for the analysis was the CONCORD data base, a programme of global surveillance of cancer survival trends, which includes the tumour records of individual patients from more than 300 population-based cancer registries. We considered all patients aged 0-99 years who were diagnosed with a primary brain tumour during 2000-2014, whether malignant or non-malignant. We presented the histology distribution of these tumours, for patients diagnosed during 2000-2004, 2005-2009, and 2010-2014. RESULTS Records were submitted from 60 countries on five continents, 67,331 for children and 671,085 for adults. After exclusion of irrelevant morphology codes, the final study population comprised 60,783 children and 602,112 adults. Only 59 of 60 countries covered in CONCORD-3 were included, because none of the Mexican records were eligible. We defined 12 histology groups for children, and 11 histology groups for adults. In children (0-14 years), the proportion of low-grade astrocytomas ranged between 6% and 50%. Medulloblastoma was the most common sub-type in countries where low-grade astrocytoma was less commonly reported. In adults (15-99 years), the proportion of glioblastomas varied between 9% and 69%. International comparisons were made difficult by wide differences in the proportion of tumours with unspecified histology, which accounted for up to 52% of diagnoses in children and up to 65% in adults. CONCLUSIONS To our knowledge, this is the first account of the global histology distribution of brain tumours, in children and adults. Our findings provide insights into the practices and the quality of cancer registration worldwide.

Objective . To examine the distribution of stage at diagnosis for 12 cancers in Kuwait, to estimate stage-specific net survival at 1 and 5 years after diagnosis, and to assess differences in stage-specific survival between Kuwait and the United States. Material and Methods . Data were obtained from the Kuwait Cancer Registry, for Kuwaiti patients diagnosed during 2000–2013, with follow-up to 31 December 2015. The distribution of Surveillance Epidemiology and End Results (SEER) Summary Stage for 12 malignancies was examined. We estimated net survival by stage up to 5 years after diagnosis, controlling for background mortality with life tables of all-cause mortality in the general population by single year of age, sex, and calendar period. Survival estimates were age-standardised using the International Cancer Survival Standard (ICSS) weights. Results . Only 14.2% of patients were diagnosed at a localised stage and 38.9% at the regional stage. The proportion of patients with known stage was 88.9% during 2000–2004 but fell to 59.4% during 2010–2013. During 2005–2009, 1- and 5-year survival for colon, rectal, breast, cervical, and prostate cancer was about 90% or higher for patients diagnosed at the localised stage. During 2004–2009, the proportion of patients diagnosed at a localised stage was lower in Kuwait than in the US for colon, breast, and lung cancer. Age-standardised 5-year net survival for all stages combined was lower in Kuwait than the US for colon, lung, and breast cancer, but stage-specific survival was similar. Conclusion . Since stage-specific survival is similar in Kuwait and the US, late stage at diagnosis is likely to be a major contributing factor to the overall lower survival in Kuwait than in the US. Increasing public awareness of cancer risk factors and symptoms and investment in early detection will be vital to reduce the proportion of patients diagnosed at a late stage and to improve survival.

Background: Gastric cancer is the 5th most common cancer in the world and 2nd leading cause of cancer deaths. It has marked geographic incidence variation. Most common in Japan, China, other East Asian countries, Eastern Europe and South America. There is sharp decrease in incidence in western countries over the past 60 years but incidence of GE junction and proximal gastric tumors is increasing. In state of Kuwait in 2012 ASR was 2.6/100,000 population (similar to other Gulf countries; apart from Oman). There are many known risk factors including eating smoked and salted food and H. pylori infection. Aim: The aim of this study is to analyze gastric cancer diagnosed cases from 2009 to 2015 in Kuwait and to analyze clinicopathological criteria and prognostic factors. Methods: A total of 145 adult patients with newly diagnosed gastric cancers were treated and followed-up at Kuwait Cancer Control Center (KCCC) between 2009-2015. Patients' data were examined retrospectively. In all cases: age, performance status, sex, ethnicity, smoking and dietary habit, tumor site, pathology, staging and type of treatment were identified. Survival analysis was done using Kaplan-Meier, and comparison was done using long-rank test. Results: The median age at diagnosis was 54 (29-94). Men represented 63.5%. 75.2% had adenocarcinoma, 14.5% gastric lymphoma, 6.2% GIST, 3.4% carcinoid and 1 case squamous cell carcinoma. For gastric adenocarcinoma, 22 were metastatic (20.2%). In spite of composing almost 25% of country population and expected high incidence in their home countries, only 19.5% of patients were Asian with known habit of spicy food intake. 31% of patients were smokers. Performance at diagnosis was ECOG 0-1 in majority. Median follow-up was 45 months (1-89) and median overall survival was 34 months (0.5-89). Almost half of tumors were poorly differentiated with signet-ring feature in 36.8%. 12.6% presented with clinically advanced tumor but after surgery the number upstaged to be 25.9% (Stage III). Tumor epicenter localization was almost equivalent with 43 (49.4%) localized proximally and 44 (50.6%) distally. Surgery was the main treatment in majority (85.1%) while radiation was used in 58.6% and chemotherapy in 74.4% (adjuvant, neoadjuvant or concomitant). 22 patients failed; 7 locoregionally, 15 had distant metastasis while 2 patients failed both locally and distantly. Close surgical margins, and proximal localization were poor prognostic factors. Age and ethnicity had no impact on outcomes in our cohort. Conclusion: Gastric adenocarcinoma in Kuwait has similar profile to that documented worldwide and regionally (apart from Oman). Proximal tumors represent a challenge and has poorer prognosis that may need more intensification of treatment. Current (neo)adjuvant treatment seem to be effective in our population. Molecular profiling and studies are needed for further understanding of this potentially curable disease.

Background: Nasopharyngeal is relatively prevalent in South East Asia and mainland China, northern Africa and Alaska. For advanced disease, there is a greater than 50% risk of recurrence after radiotherapy (RT) alone, and approx. half of all recurrences are distant failures. A meta-analysis of 6 randomized trials showed that addition of chemotherapy (CT) to RT significantly improved disease-free/ progression-free survival rates by 34% to 40% respectively. Epstein-Barr virus (EBV) has yielded significant insight into pathogenesis of NPC. It is undifferentiated form of NPC that shows most consistent worldwide association with EBV suggesting that targeted approaches should be considered for preventive and therapeutic intervention. The prognostic value of pre-treatment EBV DNA viral load for non-endemic areas proved in retrospective study conducted in Italy, disease free survival (DFS) and over all survival (OS) were significantly longer in patients with pre-treatment negative EBV DNA than in positive patients. Antiviral drugs have been used to inhibit EBV replication and target viral DNA polymerase Aim of this study is to define the efficacy of adding anti-viral treatment to eliminate PCR-DNA EBV in patients with NPC. It will also be correlated with the response rate (RR), local control, DFS, and OS. Trial design: Patients and Methods: All patients with diagnosis of nasopharyngeal squamous cell carcinoma, . Patients should have positive PCR-DNA EBV. Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions. Randomization to antiviral therapy acyclovir tablets 800 mg/day during the whole course of treatment Or Placebo. We aim to enroll 100 patients for study with 2:1 randomization. Follow up with PCR-DNA EBV will be done mid-treatment and immediately after treatment then with usual follow up of the NPC cases. Legal entity responsible for the study: Radiation Oncology Department, Kuwait Cancer Control Center. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

BACKGROUND:There is a need for informative molecular markers that provide prognostic information over and above that given by conventional pathologic parameters. This study examined the expression and potential prognostic value of c-MET in colorectal adenocarcinoma.MATERIAL AND METHODS:Two-hundred and thirty cases were evaluable after tissue microarray construction and evaluated for c-MET expression by immunohistochemistry. The results were correlated with standard clinicopathologic prognostic factors. Cases were followed up for 5 years.RESULTS:c-MET was highly expressed in 138 of 230 cases (60%). In normal tissues a negative or weak reaction was observed. Significantly higher c-MET expression was found in the metastatic group (p=0.04). No significant association was found in relation to age, sex, tumor site, tumor size, histological type, or tumor grade (p > 0.05). The 5-year disease free survival for patients with low levels of expression was significantly higher than that for patients with high levels (64% versus 45%, p=0.04).CONCLUSION:c-MET seems to be a valuable biomarker in colorectal adenocarcinoma; overexpression is a useful prognostic indicator for metastasis and patient outcome.KEYWORDS:c-MET, prognosis, colorectal adenocarcinoma, tissue microarray.

AIM:The quality of cancer registration is of great importance and the present study was conducted to assess the reliability of Kuwait Cancer Registry data on breast cancer.METHODS:Data from the clinical records extracted by a group of clinical oncologists for another study on 1,235 breast cancer cases diagnosed between 1999 and 2004 were used to audit the data held on these individuals by the Kuwait Cancer Registry (KCR). Only 902 cases met the eligibility criteria. Main measures were sex, nationality, laterality, morphology, stage of disease at time of admission to the center, type of treatment and status at last follow up (alive or dead).RESULTS:Full or high agreement between registry data and clinical oncologists collected data was recorded for sex, nationality and laterality. The rate of agreement for treatment with chemotherapy and status at last follow up was near perfect. Substantial agreement was also noted for morphology, tumor grade, TNM staging, surgical, radiotherapy and hormonal treatment. The majority of minor differences in morphology disagreements occurred when a more specific description was stated by registry staff, while major disagreement occurred due to difference in the codes used.CONCLUSIONS:The accuracy of the KCR data seems to be comparable to that found in reviews of other cancer registries. Stage was the hardest variable for the registry to collect accurate information on. KCR data could be improved by improving the quality of information provided to the registry.

UNLABELLED:Cancer registry data obtained from the Kuwait Cancer Registry at Kuwait Cancer Control Center (KCCC) of Ministry of Health, State of Kuwait. The data covers the years 1974 to 2007.AIM OF THIS STUDY:was to estimate the magnitude of the cancer problem in Kuwait over the period 1974-2007.MATERIALS AND METHODS:Age-adjusted incidence rates (ASR) with standard error (er) and 95% confidence intervals (95% CI) of age-standardized rates were estimated. Statistical significance was assessed by examining the standardized rate ratio (SRR).RESULTS:It was noted that by following the Cancer registry data there was a trend of increase in adjusted rates among both males and females. Looking into specific cancers it was noticed that comparing the ASR of colorectal cancer among Kuwaiti males, it increased by about 5 folds over the last 33 years and ranked the 1st most frequent site on the years 2003-2007. Prostate cancer incidence increased by 3 folds (14.5 cases /100,000 populations) and ranked the 4th most frequent site among Kuwaiti males. The incidence of Non Hodgkin's Lymphoma (NHL) and leukemia had increased by 1.5 to 2 folds over the same time period. The rise of lung cancer incidence declined to similar rates compared to that observed in the early 70s and 80s. For Kuwaiti females breast cancer had the highest incidence among Kuwaiti population (15 cases /100,000 populations), it increased by 3 folds (50 cases /100,000 populations) over the last 33 years. The incidence of colorectal cancer increased by about 4 folds; (13 cases /100,000 populations). NHL and leukemia increased by 2-2.5 folds over the same studied duration. Meanwhile Thyroid cancer increased by one fold.CONCLUSION AND RECOMMENDATIONS:Some of the differences in cancer rates over the last 33 years are likely to be attributable to the variation in exposure to specific etiologic factors that are caused by differences in lifestyle and habits, such as dietary, physical activity and obesity. Further research with a view to understanding these changes in cancer incidence is warranted. The need for an interventional prevention programs that vigorously involve, diet, anti-smoking and physical activity among both sexes.